MedPath

Meloxicam

Generic Name
Meloxicam
Brand Names
Anjeso, Mobic, Qmiiz, Vivlodex
Drug Type
Small Molecule
Chemical Formula
C14H13N3O4S2
CAS Number
71125-38-7
Unique Ingredient Identifier
VG2QF83CGL
Background

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.

Indication

Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain.

Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Associated Conditions
Dental Pain, Neuropathic Pain, Osteoarthritis (OA), Pain, Inflammatory, Pauciarticular juvenile rheumatoid arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Postoperative pain, Rheumatoid Arthritis
Clinical Trials
Related News

Opiate Free Multimodal Pain Pathway in Elective Foot and Ankle Surgery: A Prospective Study

Completed
Conditions
Hammertoe
Bunion of Unspecified Foot
Ankle Fractures
Achilles Tendon Surgery
Bunionette of Unspecified Foot
Interventions
Drug: Acetominophen
First Posted Date
2021-02-25
Last Posted Date
2023-04-27
Lead Sponsor
Prisma Health-Midlands
Target Recruit Count
72
Registration Number
NCT04771741
Locations
🇺🇸

Prisma Health Midlands, Columbia, South Carolina, United States

PROUD Study - Preventing Opioid Use Disorders

Phase 4
Terminated
Conditions
Opioid Use
Anesthesia
Interventions
Behavioral: Guided mindfulness exercises
Other: Self-administered aromatherapy
Drug: Tylenol/Acetaminophen
Drug: Tranexamic Acid (TXA)
First Posted Date
2021-02-23
Last Posted Date
2023-06-22
Lead Sponsor
Emory University
Target Recruit Count
57
Registration Number
NCT04766996
Locations
🇺🇸

Emory University Orthopaedic and Spine Hospital, Atlanta, Georgia, United States

Does Meloxicam Provide as Much Pain Relief as Opioids After Shoulder Surgery?

Phase 3
Conditions
Shoulder Pain
Interventions
Procedure: Preoperative Interscalene Nerve Block
Procedure: arthroscopic labral repair
First Posted Date
2021-01-26
Last Posted Date
2021-01-26
Lead Sponsor
Rothman Institute Orthopaedics
Target Recruit Count
96
Registration Number
NCT04725357
Locations
🇺🇸

Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States

Drug-drug Interaction Between DWP14012 and Three Different Kinds of NSAIDs

Phase 1
Conditions
Healthy Male Volunteers
Interventions
First Posted Date
2020-07-29
Last Posted Date
2020-07-29
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
110
Registration Number
NCT04490434
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Bawei Shenqi Pill in the Treatment of Ankylosing Spondylitis

Phase 2
Conditions
Ankylosing Spondylitis
Interventions
Drug: Bawei Shenqi Pill
Drug: Bawei Shenqi Pill placebo
First Posted Date
2020-07-21
Last Posted Date
2020-08-14
Lead Sponsor
Shanghai University of Traditional Chinese Medicine
Target Recruit Count
80
Registration Number
NCT04480359
Locations
🇨🇳

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China

Pharmacokinetic and Tolerance Study of Meloxicam Eye Drops in Healthy Volunteers

Phase 1
Conditions
Healthy Volunteers
Interventions
First Posted Date
2020-03-26
Last Posted Date
2020-04-28
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
80
Registration Number
NCT04322175
Locations
🇨🇳

Institution of Drug Clinical Trials, Beijing, Beijing, China

Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials

Phase 2
Completed
Conditions
Axial Spondyloarthritis
Interventions
First Posted Date
2019-10-03
Last Posted Date
2023-12-05
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
42
Registration Number
NCT04115098
Locations
🇺🇸

The University of Texas Health Science Center at Houston, Houston, Texas, United States

The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

First Posted Date
2019-07-01
Last Posted Date
2019-07-01
Lead Sponsor
Rothman Institute Orthopaedics
Target Recruit Count
216
Registration Number
NCT04003350
Locations
🇺🇸

Rothman Institute, Philadelphia, Pennsylvania, United States

Maximizing Outcomes in Treating Acute Migraine

Phase 3
Completed
Conditions
Migraine
Interventions
Drug: AXS-07 (MoSEIC meloxicam and rizatriptan)
Drug: Placebo
First Posted Date
2019-03-29
Last Posted Date
2023-08-24
Lead Sponsor
Axsome Therapeutics, Inc.
Target Recruit Count
1594
Registration Number
NCT03896009
Locations
🇺🇸

Clinical Research Site, Seattle, Washington, United States

A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2018-09-25
Last Posted Date
2019-11-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT03684265
Locations
🇷🇺

City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow, Moscow, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy